Format

Send to

Choose Destination

See 1 citation found by title matching your search:

Pharmacognosy Res. 2013 Jan;5(1):10-6. doi: 10.4103/0974-8490.105640.

Anti-atherogenic and anti-ischemic potentials of Croton membranaceus observed during sub-chronic toxicity studies.

Author information

1
Department of Pharmacology, University of Ghana Medical School, Ghana.

Abstract

BACKGROUND:

Croton membranaceus (CM) is used for benign prostate hyperplasia treatment.

OBJECTIVE:

Sub-chronic toxicity studies are non-existent and provided the basis for this study.

MATERIALS AND METHODS:

90 days oral administration of a low dose (LD) (30 mg/kg b. wt.), medium dose (MD) (150 mg/kg b. wt.), and high dose (HD) (300 mg/kg b. wt.) CM aqueous root extract to 3 groups (n=6 each) of male Sprague-Dawley rats, alongside a control group, was undertaken. Urinalysis, hepato-renal function tests, lipid profile, cardiac enzymes, and routine hematology tests were performed.

RESULTS:

Triglyceride levels (C=1.05±0.19, LD=0.64±0.08, MD=0.55±0.04, HD=0.50±0.02 mmol/L) were significantly reduced (P<0.05). Very low density lipoprotein (C=0.48±0.09, LD=0.29±0.04, MD=0.25±0.02, HD=0.23±0.01 mmol/L) decreased significantly (P<0.05). Cardiac enzymes-creatinine kinase (C=568±172, LD=315±79, MD=441±209, HD=286±81 IU/L) decreased markedly (P<0.05) alongside lactate dehydrogenase (C=2675±875, LD=1667±1229, MD=1186±442, HD=855±239 IU/L) (P<0.05).

CONCLUSION:

C. membranaceus aqueous root extract is non-toxic but demonstrates anti-atherogenic and anti-ischemic potentials.

KEYWORDS:

Anti-atherogenic; Croton membranaceus; anti-ischemic; sub-chronic; toxicity

Supplemental Content

Full text links

Icon for Medknow Publications and Media Pvt Ltd Icon for PubMed Central
Loading ...
Support Center